SciSparc Ltd. (Nasdaq: SPRC) Up Over 6% Pre Market, Keep an Eye on SPRC Today

SciSparc Ltd. (Nasdaq: SPRC) SciSparc Ltd. (Nasdaq: SPRC) Signs Non-Binding Letter of Intent to Spin Off Advanced Clinical Stage Pharmaceutical Portfolio 10XProTrader Member, This is Kevin Vander with "10XProTrader", delivering you your breakout alert for today's trading session 7/15, we are introducing SciSparc Ltd. (Nasdaq: SPRC). In the dynamic world of biotechnology and pharmaceuticals, SciSparc Ltd. (Nasdaq: SPRC) is carving out a unique niche. Amidst significant market fluctuations earlier this year, the company is demonstrating resilience and innovation through strategic clinical and corporate initiatives. These efforts are not only stabilizing the company but also setting the stage for substantial long-term growth. With groundbreaking clinical trials and bold spin-off strategies, SciSparc is on a path to unlock considerable value for its shareholders. As the company continues to make strides in medical research and strategic business moves, investors have ample reasons to be optimistic about SciSparc's future potential. SciSparc Ltd. (Nasdaq: SPRC) is emerging as a noteworthy player in the biotech and pharmaceutical sector, despite facing significant market fluctuations earlier this year. The company is actively pursuing clinical and corporate strategies aimed at achieving stability and long-term growth, thereby enhancing shareholder value. [Clinical Trial Advancements: Autism, Tourette's, Alzheimer's]( SciSparc is advancing its clinical research with a robust pipeline of trials targeting major neurological disorders. Key projects include: - Tourette's Syndrome: A phase IIb trial for SCI-110 is underway, presenting a potential breakthrough for this condition. - Alzheimer's Disease: A phase II trial has been completed, offering promising insights for future treatments. - Autism Spectrum Disorder: A notable trial for SCI-210, focusing on children with autism, is in progress. This double-blind, placebo-controlled trial aims to address core symptoms of autism, potentially improving the quality of life for affected children and their families. SciSparc's recent patent acquisitions, including those for the treatment and prevention of depression, further bolster its competitive edge and intellectual property portfolio. Check out their most recent Press Release below! [SciSparc Signs Non-Binding Letter of Intent to Spin Off Advanced Clinical Stage Pharmaceutical Portfolio]( [According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million]( [TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today it signed a non-binding letter of intent (the “LOI”) to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc. (collectively, the “Target Assets”). The LOI references a proposed asset and share purchase agreement (the “Agreement”), the definitive agreement of which is to be negotiated between the Company and Miza III Ventures Inc. (“Miza”) (TSXV: MIZA.P), a publicly traded company on the Toronto Stock Exchange Venture in Canada.]( The Agreement is based on the approximate total USD 3.3 million (CAD 4.5 million) enterprise value of Miza, when including its USD 1.0 million cash position, and an approximate USD 11.6 million (CAD 15.8 million) value of SciSparc’s assets. Pursuant to the LOI, SciSparc will sell, assign, convey and transfer to Miza the Target Assets in consideration for 63,300,000 common shares of Miza and up to 48,000,000 Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, SciSparc would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately 75% to a maximum of 84.53%, will be active in both the pharmaceutical and supplement sectors. [The Agreement aligns with SciSparc's strategy of creating value for its shareholders and follows the merger agreement and transaction concerning AutoMax Motors Ltd., as previously announced by SciSparc on April 11, 2024.]( SciSparc’s pharmaceutical portfolio includes SCI-110 for treating persons with Tourette syndrome, which is subject to a phase IIb clinical trial, SCI-110 for treating persons with Alzheimer’s disease, the phase II clinical trial of which has been completed, and SCI-210 for treating children with autism, subject to a randomized, double-blind and placebo-controlled trial that commenced in the first quarter of 2024. Strategic Spin-off: A Game Changer [On July 8th, SciSparc announced its intent to spin off its advanced clinical-stage drug portfolio to Miza III Ventures Inc., a company listed on the Toronto Stock Exchange Venture. This spin-off, valued at approximately $11.6 million, involves transferring assets to Miza in exchange for 63.3 million common shares and up to 48 million contingent rights. SciSparc will retain a dominant stake of 75% to 84.53% in the merged entity.]( This strategic move could be set to unlock significant shareholder value by diversifying SciSparc's revenue streams and reducing exposure to the volatile biotech market. [It builds on their April merger with AutoMax, aimed at creating new revenue streams and exploring new markets.]( Looking Ahead SciSparc's focus on clinical trials and strategic partnerships highlights its growth potential. The ongoing spin-off plans and clinical trial progress are pivotal for the company's future trajectory and investor sentiment. For investors interested in biotech innovations and willing to navigate market volatility, SciSparc presents a compelling opportunity. Stay tuned for updates on these strategic initiatives and trials, which will shape SciSparc's future. [Get SciSparc Ltd. (Nasdaq: SPRC)]( your radars and watchlists this morning! Pay very close attention to your email inbox, your next alert is just around the corner. Yours for greater gains, Kevin Vander Publisher, 10XProTrader.com Investment Research Sources: [SciSparc (SPRC) Stock Price, News & Analysis]( [SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company | Markets Insider]( [SciSparc Ltd. (SPRC) Stock Price, Quote & News]( [SciSparc – Groundbreaking Therapies]( [SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company (yahoo.com)]( [SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression (yahoo.com)]( to Acquire AutoMax (yahoo.com)]( You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2024 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2024 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not accept stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.